Objective: Acinetobacter spp. poses a significant public health challenge due to multidrug-resistant infections, particularly in intensive care units (ICUs). This study aimed to evaluate the antibiotic resistance rates of Acinetobacter spp. strains isolated from ICU patients between 2020 and 2025 at our hospital.

Methods: A retrospective analysis was conducted on Acinetobacter spp. isolates obtained from ICU patients. Clinical samples were collected under sterile conditions, processed with standard microbiological techniques, and antibiotic susceptibility was tested using the VITEK-2 Compact system (bioMérieux, France). Data were retrieved from the hospital’s laboratory information system.

Results: A total of 654 isolates were evaluated, with tracheal aspirate being the most common sample type (60.0%), followed by blood (13.0%), sputum (9.3%), wound (5.5%), urine (5.0%), catheter (4.7%), cerebrospinal fluid (1.5%), and respiratory tract specimens (1.2%). The highest susceptibility rate was observed with amikacin (16.1%), whereas ciprofloxacin showed the lowest (0.8%). Other antibiotics exhibited similarly low susceptibility rates.

Conclusion: Multidrug-resistant Acinetobacter spp. strains complicate the treatment of intensive care unit infections. Monitoring current resistance profiles and strengthening infection control measures are critically important to prevent the spread of these pathogens and to improve treatment outcomes.